Go to
current issue
-
Cybersecurity and cardiac implantable electronic devices Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-04-03 Bryce Alexander; Adrian Baranchuk
-
Twice-yearly inclisiran injections halve LDL-cholesterol levels Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-31 Irene Fernández-Ruiz
-
Evaluation and management of heart failure with preserved ejection fraction Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-30 Barry A. Borlaug
-
Cardiovascular effects of electronic cigarettes Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-30 Holly R. Middlekauff
The available literature suggests that electronic cigarettes (e-cigarettes), although not without risk, might decrease cardiovascular risk in long-term smokers of tobacco cigarettes who switch to e-cigarettes. However, to safeguard our youth, e-cigarettes must be required to meet product standards, all flavourings must be banned and laws regulating e-cigarette sales must be strictly enforced. The available
-
Single-cell RNA sequencing in cardiovascular development, disease and medicine Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-30 David T. Paik; Sangkyun Cho; Lei Tian; Howard Y. Chang; Joseph C. Wu
-
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-30 Joerg Herrmann
-
Is salt substitution ready for prime time? Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-27 Bruce Neal; Matti Marklund
-
Vascular toxic effects of cancer therapies Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-26 Joerg Herrmann
-
Novel gut microbiota-derived metabolite promotes platelet thrombosis via adrenergic receptor signalling Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-24 Karina Huynh
-
T cell subsets and functions in atherosclerosis Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-16 Ryosuke Saigusa; Holger Winkels; Klaus Ley
-
Previous MI attenuates emergency haematopoiesis and inflammation Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-10 Karina Huynh
-
The effects of endurance exercise on the heart: panacea or poison? Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-09 Gemma Parry-Williams; Sanjay Sharma
-
Inhibiting fatty acid oxidation promotes cardiomyocyte proliferation Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-09 Gregory B. Lim
-
COVID-19 and the cardiovascular system Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-03-05 Ying-Ying Zheng; Yi-Tong Ma; Jin-Ying Zhang; Xiang Xie
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system. Therefore, particular attention should be given to cardiovascular protection during treatment for COVID-19.
-
Plexin D1 is a mechanosensor that regulates the site-specific distribution of atherosclerosis. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-25 Irene Fernández-Ruiz
-
LVAD versus balloon pump in patients with AMI. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-25 Karina Huynh
-
Cocoa might improve walking performance in PAD. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-25 Karina Huynh
-
Ketogenesis in arrhythmogenic cardiomyopathy. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-25 Karina Huynh
-
Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-24 Marc Dewey,Maria Siebes,Marc Kachelrieß,Klaus F Kofoed,Pál Maurovich-Horvat,Konstantin Nikolaou,Wenjia Bai,Andreas Kofler,Robert Manka,Sebastian Kozerke,Amedeo Chiribiri,Tobias Schaeffter,Florian Michallek,Frank Bengel,Stephan Nekolla,Paul Knaapen,Mark Lubberink,Roxy Senior,Meng-Xing Tang,Jan J Piek,Tim van de Hoef,Johannes Martens,Laura Schreiber,
-
Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-20 Yi Tan,Zhiguo Zhang,Chao Zheng,Kupper A Wintergerst,Bradley B Keller,Lu Cai
-
Macrophages produce collagen for myocardial scar formation. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-17 Gregory B Lim
Macrophages directly contribute collagen to scar formation as part of heart regeneration in zebrafish and heart repair in mice; this finding develops the current paradigm of collagen deposition for scar formation being generated exclusively via macrophage-mediated activation of cardiac fibroblasts to myofibroblasts.
-
Dual apoC-II mimetic and apoC-III antagonist for hypertriglyceridaemia. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-13 Karina Huynh
-
Neighbourhood built environment and cardiovascular disease: knowledge and future directions. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-12 Mohammad Javad Koohsari,Gavin R McCormack,Tomoki Nakaya,Koichiro Oka
-
New developments in gene editing for Duchenne muscular dystrophy. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-11 Irene Fernández-Ruiz
-
Reappraisal of LQTS-causing genes. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-10 Gregory B Lim
-
Diagnostic imaging of cardiac amyloidosis. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-10 Ana Martinez-Naharro,A John Baksi,Philip N Hawkins,Marianna Fontana
-
5-year safety of TAVI in intermediate-risk patients. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-06 Gregory B Lim
-
Coconut oil raises LDL-cholesterol levels. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-06 Gregory B Lim
-
Sphingolipids are biomarkers of coronary disease. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-06 Gregory B Lim
-
Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-03 Elaheh Karbassi,Aidan Fenix,Silvia Marchiano,Naoto Muraoka,Kenta Nakamura,Xiulan Yang,Charles E Murry
-
Neutrophils as regulators of cardiovascular inflammation. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-29 Carlos Silvestre-Roig,Quinte Braster,Almudena Ortega-Gomez,Oliver Soehnlein
-
Important distinction between acute coronary syndromes and Takotsubo syndrome. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-29 Vincenzo Marafioti,Giulia Turri,Salvatore Monaco
-
Intracoronary mitochondrial transplantation. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-24 Gregory B Lim
-
Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-23 Gerald F Watts,Samuel S Gidding,Pedro Mata,Jing Pang,David R Sullivan,Shizuya Yamashita,Frederick J Raal,Raul D Santos,Kausik K Ray
-
Platelet-derived growth factor AB promotes wound repair after MI. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-23 Karina Huynh
-
Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-22 Luigi Adamo,Cibele Rocha-Resende,Sumanth D Prabhu,Douglas L Mann
-
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-17 Davide Capodanno,Deepak L Bhatt,John W Eikelboom,Keith A A Fox,Tobias Geisler,C Michael Gibson,Jose Ramon Gonzalez-Juanatey,Stefan James,Renato D Lopes,Roxana Mehran,Gilles Montalescot,Manesh Patel,P Gabriel Steg,Robert F Storey,Pascal Vranckx,Jeffrey I Weitz,Robert Welsh,Uwe Zeymer,Dominick J Angiolillo
-
The challenge of an expanded therapeutic window in pulmonary hypertension. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-16 Simon Stewart,Geoffrey A Strange,David Playford
-
AKCEA-APO(a)-LRx lowers Lp(a) levels in patients. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-16 Irene Fernández-Ruiz
-
Alcohol abstinence reduces AF recurrence. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-16 Irene Fernández-Ruiz
-
HDACs as a therapeutic target in HFpEF. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-16 Irene Fernández-Ruiz
-
Reappraisal of the safety and effectiveness of Impella pumps. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-14 Muthiah Vaduganathan,Mandeep R Mehra
-
The Apple Watch can detect atrial fibrillation: so what now? Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2019-12-23 Gregory M Marcus
-
Non-HDL cholesterol levels linked with long-term risk of CVD. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2019-12-18 Karina Huynh
-
GPR146 is a potential new therapeutic target for lipid lowering. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2019-12-17 Irene Fernández-Ruiz
-
Stem cell therapy improves heart function by triggering an acute immune response. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Karina Huynh
-
Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2019-12-09 Pankaj Garg, Andrew J. Swift, Liang Zhong, Carl-Johan Carlhäll, Tino Ebbers, Jos Westenberg, Michael D. Hope, Chiara Bucciarelli-Ducci, Jeroen J. Bax, Saul G. Myerson
-
Udenafil to FUEL exercise performance in individuals with Fontan physiology. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Gregory B Lim
Udenafil, a phosphodiesterase type 5 inhibitor, improves measures of exercise performance at the ventilatory anaerobic threshold in individuals with Fontan physiology.
-
Dapagliflozin for HFrEF - improved outcomes across all ages. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Karina Huynh
-
Anti-inflammatory therapy for secondary prevention after MI. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Gregory B Lim
-
Early aortic valve surgery reduces mortality. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Karina Huynh
In the RECOVERY trial, asymptomatic patients with very severe aortic stenosis who underwent early surgery had lower risk of cardiovascular death than those treated using a conservative-care strategy.
-
Dissecting the benefits of sacubitril-valsartan for heart failure. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Irene Fernández-Ruiz
New analyses of the PARAGON-HF and PARADIGM-HF trials indicate that sacubitril–valsartan treatment might be beneficial in patients with heart failure with mildly reduced left ventricular ejection fraction and that the benefit might be greater in women than in men.
-
Role of rivaroxaban after TAVI. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Irene Fernández-Ruiz
Results of the GALILEO trial presented at the AHA Scientific Sessions 2019 indicate that a strategy with rivaroxaban 10 mg daily is associated with a higher risk of death or thromboembolic events and a higher risk of bleeding than an antiplatelet-based strategy.
-
Assessing hypertension therapies: randomization or confounding by indication? Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-02-01 Sverre E Kjeldsen,Ingrid Os
Findings from a large, international study comprising 4.9 million people with mild hypertension suggest that thiazide and thiazide-like diuretics might be more effective and safer than other first-line antihypertensive drugs. However, the study was not randomized, and the findings might be explained by a phenomenon known as ‘confounding by indication’.
-
Predicting longevity using metabolomics: a novel tool for precision lifestyle medicine? Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2019-11-21 Jean-Pierre Després
-
Exercise protects against cardiovascular disease by modulating immune cell supply. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-01 Irene Fernández-Ruiz
-
Pro-inflammatory atherogenic role of platelets. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-01 Gregory B Lim
-
Early mortality after AF ablation. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-01 Karina Huynh
According to data from a national representative US-based database, early mortality was observed in almost 1 in 200 patients with atrial fibrillation undergoing catheter ablation.
-
HDAC9 linked to aortic calcification. Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2020-01-01 Irene Fernández-Ruiz
-
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype Nat. Rev. Cardiol. (IF 17.42) Pub Date : 2019-11-04 Kelsie E. Oatmen, Elizabeth Cull, Francis G. Spinale
京公网安备 11010802027423号